Alkem Laboratories invests $50M in biotech startup Enzene Biosciences

Alkem Laboratories subsidiary Enzene Biosciences (Enzene) has raised $50 million from Alkem Laboratories, Eight Roads Ventures, and F-Prime Capital.

The company wants to expand in India and the US by using the funds it has raised to enhance production capabilities.

Enzene, a company with its headquarters in Pune, has developed fully integrated biotech process development and production capabilities across many modalities and platforms. It has created a captive pipeline of biosimilars that have been sold to multinational pharmaceutical companies through out-licensing agreements. Additionally, it provides full-range contract development and production services to biotechnology companies.

Enzene offers a range of biologics services, including the ability to execute good manufacturing practises (GMP) and develop clones, all of which are supported by bioreactors with capacities ranging from 20 to 2,000 litres. Its primary product areas include biosimilars, novel biologics, synthetic peptides, and phytopharmaceuticals.

Commenting on the funding Dr Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures. said  “We are thrilled to be partnering with Alkem Laboratories and Enzene to build a global biosimilars and biologics powerhouse out of India,” 

Dr. Himanshu Gadgil, CEO of Enzene Biosciences Ltd., planned to carry out the company’s commitment to providing innovative and reasonably priced biomanufacturing for novel biologics and biosimilars globally.

Leave a Comment